Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam
is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for is urgent. We demonstrate the efficacy of aztreonam-avibactam (ATM-AVI) a...
Gespeichert in:
Veröffentlicht in: | Antimicrobial agents and chemotherapy 2017-10, Vol.61 (10) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for
is urgent. We demonstrate the
efficacy of aztreonam-avibactam (ATM-AVI) against
and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of
, addressing an unmet medical need. |
---|---|
ISSN: | 0066-4804 1098-6596 |
DOI: | 10.1128/AAC.00777-17 |